Pharmacologic Characterization of Omidenepag Isopropyl, a Novel Selective EP2 Receptor Agonist, as an Ocular Hypotensive Agent.
| Author | |
|---|---|
| Abstract |
:
The objective of this study was to investigate the pharmacologic characteristics of omidenepag isopropyl (OMDI), a compound developed as a novel intraocular pressure (IOP)-lowering agent, with better IOP control and fewer side effects than other prostanoid receptor agonists such as prostaglandin F receptor (FP) agonists. |
| Year of Publication |
:
2018
|
| Journal |
:
Investigative ophthalmology & visual science
|
| Volume |
:
59
|
| Issue |
:
1
|
| Number of Pages |
:
145-153
|
| Date Published |
:
2018
|
| ISSN Number |
:
0146-0404
|
| URL |
:
http://iovs.arvojournals.org/article.aspx?doi=10.1167/iovs.17-22745
|
| DOI |
:
10.1167/iovs.17-22745
|
| Short Title |
:
Invest Ophthalmol Vis Sci
|
| Download citation |
